LD-2 disclosure · 3rd Quarter - Report
EMERGENT BIOSOLUTIONS
Client
- Description
- Pharmaceutical company.
- Location
- Maryland · United States of America
Registrant
- Description
- Consulting firm.
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
3 issuesBudget/Appropriations
Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY2026. Opioid and heroin addiction legislation, naloxone access and awareness.
Lobbyistsmr DONALD KENT
TargetedSENATE
Health Issues
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act, Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY2026, Opioid crisis legislation, naloxone access and awareness, FY2026 NDAA provisions related to biological and chemical defense and access to naloxone.
LobbyistsMARY BETH SAVARY TAYLOR · mr DONALD KENT · GREG D'ANGELO
TargetedSENATE · HOUSE OF REPRESENTATIVES · Office of Management & Budget (OMB)
Defense
National Defense Authorization Act for FY2026, provisions related to biological and chemical defense and access to naloxone.
Lobbyistsmr DONALD KENT